Trial	Intervention(s) and comparator(s)	Participants included in analysis (N)	Deaths (N)	Deaths (% of participants)	Participants with at least one adverse event (N)	Participants with at least one adverse event (%)	Participants with at least one severe/serious adverse event (N)	Participants with at least one severe/serious adverse event (%)
Atabek 2008	I: metformin + diet and physical activity advice	90	0	0	2	2.2	0	0
	C: placebo + diet and physical activity advice	30	0	0	0	0.0	0	0
Berkowitz 2003	I: behavioural programme + sibutramine	43	0	0	6	14.0	‐	‐
	C: behavioural programme + placebo	39	0	0	3	7.7	‐	‐
Berkowitz 2006	I: behavioural therapy programme + sibutramine	368	0	0	327	88.9	10	2.7
	C: behavioural therapy programme + placebo	130	0	0	111	85.4	1	0.8
Chanoine 2005	I: orlistat + diet + exercise + behavioural therapy	352	0	0	341	97	11	3
	C: placebo + diet + exercise + behavioural therapy	181	0	0	170	94	5	3
Clarson 2009	I: metformin + lifestyle intervention	14	0	0	0	0	0	0
	C: lifestyle intervention only	17	0	0	0	0	0	0
Franco 2014	I: sibutramine + dietary guidance	63	‐	‐	8	13.4	0	0
	C: placebo + dietary guidance	63	‐	‐	3	4.9	0	0
Freemark 2001	I: metformin	15	0	0	4	26.7	0	0
	C: placebo	17	0	0	1	5.9	0	0
Garcia‐Morales 2006	I: sibutramine + diet + exercise	23	0	0	10	43.5	0	0
	C: placebo + diet + exercise	23	0	0	10	43.5‐	0	0
Godoy‐Matos 2005	I: sibutramine + hypocaloric diet + exercise	30	0	0	‐a	‐	0	0
	C: placebo + hypocaloric diet + exercise	30	0	0	‐a	‐	0	0
Kendall 2013	I: metformin + healthy lifestyle advice	74	0	0	20	27.0	0	0
	C: control + healthy lifestyle advice	77	0	0	8	10.4	0	0
Maahs 2006	I: orlistat + diet and exercise therapy	20	1	5.0	‐	‐	1	5.0
	C: placebo + diet and exercise therapy	20	0	0	‐	‐	0	0
Mauras 2012	I: metformin + diet/exercise intervention	35	0	0	‐	‐	0	0
	C: diet/exercise intervention	31	0	0	‐	‐	0	0
NCT00001723	I: orlistat + behavioural weight loss programme	100	0	0	95	95	0	0
	C: placebo + behavioural weight loss programme	100	0	0	94	94	2	2
Ozkan 2004	I: conventional treatment + orlistat	22	0	0	22	100	‐	‐
	C: conventional treatment	20	0	0	0	0	‐	‐
Prado 2012	I: metformin + nutritional guide and exercise programme	10	0	0	‐	‐	0	0
	C: placebo + nutritional guide and exercise programme	9	0	0	‐	‐	0	0
Rezvanian 2010	I1: metformin + healthy eating and physical activity advice	45	0	0	7	15.6	0	0
	I2: fluoxetine + healthy eating and physical activity advice	45	0	0	‐	‐	0	0
	I3: metformin and fluoxetine + healthy eating and physical activity advice	45	0	0	‐	‐	0	0
	C: placebo + healthy eating and physical activity advice	45	0	0	‐	‐	0	0
Srinivasan 2006	I: metformin first then placebo + "standardised information on healthy eating and exercise"	13	0	0	‐b	‐	0	0
	C: placebo first then metformin + "standardised information on healthy eating and exercise"	15	0	0	‐b	‐	0	0
Van Mil 2007	I: sibutramine + energy‐restricted diet and exercise plan	12	0	0	12	100	‐	‐
	C: placebo + energy‐restricted diet and exercise plan	12	0	0	9	75	‐	‐
Wiegand 2010	I: metformin + multiprofessional lifestyle intervention	36	0	0	8	22.2	‐	‐
	C: placebo + multiprofessional lifestyle intervention	34	0	0	13	38.2	‐	‐
Wilson 2010	I: metformin + lifestyle intervention	38	0	0	‐c	‐	2	5.3
	C: placebo + lifestyle intervention	38	0	0	‐c	‐	0	0
Yanovski 2011	I: metformin + dietitian‐administered weight‐reduction programme	53	0	0	‐d	‐	0	0
	C: placebo + dietitian‐administered weight‐reduction programme	47	0	0	‐d	‐	0	0
"‐" denotes not reported. aNumber of participants with one or multiple adverse events: sibutramine group 47 events in 30 participants; placebo group 45 events in 30 participants. bTwo participants were unable to tolerate metformin 1000 mg twice daily because of nausea and were switched to metformin 750 mg twice daily with slower dose increments. cNumber of participants with one or multiple adverse events: metformin group: 52 events in 38 participants; placebo group: 43 events in 38 participants. dA total of 9/53 (17%) metformin‐treated children were unable to take the highest dose of 2000 mg/d and were prescribed doses ranging from 500 mg/d to 1500 mg/d; number of participants with one or multiple adverse events: metformin group: 64 events in 53 participants; placebo group: 25 events in 47 participants. C: comparator; I: intervention; n: number pf participants.